InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,442.00
(
2.14%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,866.94
(
-0.04%
)
Post# of 350
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

surf1944

Send PM Follow Ignore
Followers 467
Posts 26917
Boards Moderated 2
Alias Born 09/11/2006

surf1944

Re: surf1944 post# 278

Thursday, 05/24/2012 9:26:10 AM

Thursday, May 24, 2012 9:26:10 AM

Post# of 350
8:31AM Xenoport Submits Investigational new drug application for XP23829 as a potential treatment of RRMS (XNPT) 5.87 : Co announced that it has submitted an Investigational New Drug application to the FDA to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis (RRMS). Following clearance of the IND by the FDA, the first Phase 1 clinical trial to be conducted in healthy subjects will commence.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up